Current evidence and practical guidance for the use of sodium–glucose co-transporter-2 inhibitors in type 2 diabetes
24/03/2021
Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.